JDRF, PureTech Try Nonprofit Ownership To Fill Funding Gap
Executive Summary
Call it venture philanthropy with a twist: if all goes to plan, the Juvenile Diabetes Research Foundation will co-own a series of biotech companies dedicated to type 1 diabetes treatments without violating tax code, thanks to a structure created by Boston’s PureTech Ventures.
You may also be interested in...
AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.
With AAVLife Debut, Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.
The Longest Round: NovImmune’s Eight-Year Series B
Several biotechs have kept a private financing round open for several years and extended beyond $100 million, but Swiss antibody firm NovImmune is taking the concept farther than anyone.